Vaxart, Inc. (VXRT)
USD 0.34
(-10.23%)
USD 0.34
(-10.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.24 Million USD | 63.06% |
| 2022 | -22.3 Million USD | 82.94% |
| 2021 | -130.73 Million USD | -9.26% |
| 2020 | -119.66 Million USD | -967.17% |
| 2019 | -11.21 Million USD | -42.93% |
| 2018 | -7.84 Million USD | -120.28% |
| 2017 | 38.67 Million USD | 322.29% |
| 2016 | -17.4 Million USD | 64.49% |
| 2015 | -49 Million USD | -12.13% |
| 2014 | -43.7 Million USD | 46.51% |
| 2013 | -81.7 Million USD | -22.31% |
| 2012 | -66.8 Million USD | 29.17% |
| 2011 | -94.31 Million USD | -76.07% |
| 2010 | -53.56 Million USD | -0.01% |
| 2009 | -53.55 Million USD | 41.3% |
| 2008 | -91.23 Million USD | 37.45% |
| 2007 | -145.86 Million USD | -723.98% |
| 2006 | 23.37 Million USD | 198.02% |
| 2005 | 7.84 Million USD | 111.06% |
| 2004 | -70.91 Million USD | 19.75% |
| 2003 | -88.36 Million USD | -70.79% |
| 2002 | -51.73 Million USD | 1.81% |
| 2001 | -52.69 Million USD | -148.8% |
| 2000 | 107.98 Million USD | -3.76% |
| 1999 | 112.19 Million USD | -4.19% |
| 1998 | 117.1 Million USD | -0.51% |
| 1997 | 117.7 Million USD | 81.08% |
| 1996 | 65 Million USD | 67.1% |
| 1995 | 38.9 Million USD | 69.13% |
| 1994 | 23 Million USD | 32.95% |
| 1993 | 17.3 Million USD | -2.26% |
| 1992 | 17.7 Million USD | 176.56% |
| 1991 | 6.4 Million USD | -4.48% |
| 1990 | 6.7 Million USD | 11.67% |
| 1989 | 6 Million USD | -24.05% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -20.15 Million USD | -566.88% |
| 2024 Q1 | -3.02 Million USD | 63.33% |
| 2023 Q1 | -26.91 Million USD | -20.67% |
| 2023 Q2 | -22.28 Million USD | 17.23% |
| 2023 Q3 | -11.98 Million USD | 46.19% |
| 2023 Q4 | -8.24 Million USD | 31.26% |
| 2023 FY | -8.24 Million USD | 63.06% |
| 2022 Q3 | -28.6 Million USD | 63.7% |
| 2022 Q4 | -22.3 Million USD | 22.0% |
| 2022 Q1 | -110.48 Million USD | 15.49% |
| 2022 FY | -22.3 Million USD | 82.94% |
| 2022 Q2 | -78.78 Million USD | 28.69% |
| 2021 Q4 | -130.73 Million USD | 15.37% |
| 2021 FY | -130.73 Million USD | -9.26% |
| 2021 Q2 | -159.11 Million USD | -5.6% |
| 2021 Q1 | -150.67 Million USD | -25.92% |
| 2021 Q3 | -154.48 Million USD | 2.91% |
| 2020 FY | -119.66 Million USD | -967.17% |
| 2020 Q3 | -130.7 Million USD | -207.81% |
| 2020 Q2 | -42.46 Million USD | -53.12% |
| 2020 Q4 | -119.66 Million USD | 8.45% |
| 2020 Q1 | -27.73 Million USD | -147.33% |
| 2019 FY | -11.21 Million USD | -42.93% |
| 2019 Q1 | -4.13 Million USD | 47.28% |
| 2019 Q2 | -12.63 Million USD | -205.49% |
| 2019 Q4 | -11.21 Million USD | 23.15% |
| 2019 Q3 | -14.59 Million USD | -15.47% |
| 2018 Q3 | -13.83 Million USD | 28.72% |
| 2018 Q1 | -12.54 Million USD | 56.89% |
| 2018 FY | -7.84 Million USD | -120.28% |
| 2018 Q4 | -7.84 Million USD | 43.28% |
| 2018 Q2 | -19.4 Million USD | -54.68% |
| 2017 Q1 | -11.4 Million USD | 69.68% |
| 2017 Q4 | -29.1 Million USD | -50.78% |
| 2017 FY | 38.67 Million USD | 322.29% |
| 2017 Q3 | -19.3 Million USD | -10.92% |
| 2017 Q2 | -17.4 Million USD | -52.63% |
| 2016 Q2 | -49 Million USD | -64.43% |
| 2016 FY | -17.4 Million USD | 64.49% |
| 2016 Q3 | -45.2 Million USD | 7.76% |
| 2016 Q1 | -29.8 Million USD | 21.78% |
| 2016 Q4 | -37.6 Million USD | 16.81% |
| 2015 FY | -49 Million USD | -12.13% |
| 2015 Q4 | -38.1 Million USD | 14.19% |
| 2015 Q3 | -44.4 Million USD | -1.6% |
| 2015 Q2 | -43.7 Million USD | 28.94% |
| 2015 Q1 | -61.5 Million USD | 3.45% |
| 2014 Q1 | -80.1 Million USD | -55.84% |
| 2014 Q2 | -81.7 Million USD | -2.0% |
| 2014 FY | -43.7 Million USD | 46.51% |
| 2014 Q4 | -63.7 Million USD | -10.4% |
| 2014 Q3 | -57.7 Million USD | 29.38% |
| 2013 Q3 | -60.8 Million USD | 8.98% |
| 2013 FY | -81.7 Million USD | -22.31% |
| 2013 Q4 | -51.4 Million USD | 15.46% |
| 2013 Q2 | -66.8 Million USD | 4.93% |
| 2013 Q1 | -70.26 Million USD | 5.19% |
| 2012 Q2 | -92.64 Million USD | 2.35% |
| 2012 Q3 | -66.32 Million USD | 28.42% |
| 2012 Q4 | -74.11 Million USD | -11.74% |
| 2012 FY | -66.8 Million USD | 29.17% |
| 2012 Q1 | -94.87 Million USD | -0.6% |
| 2011 Q1 | -59.09 Million USD | -10.32% |
| 2011 Q2 | -86.61 Million USD | -46.58% |
| 2011 Q3 | -92.94 Million USD | -7.31% |
| 2011 Q4 | -94.31 Million USD | -1.47% |
| 2011 FY | -94.31 Million USD | -76.07% |
| 2010 FY | -53.56 Million USD | -0.01% |
| 2010 Q1 | -141.66 Million USD | -164.5% |
| 2010 Q2 | -32.45 Million USD | 77.09% |
| 2010 Q4 | -53.56 Million USD | -43.68% |
| 2010 Q3 | -37.28 Million USD | -14.87% |
| 2009 Q3 | -22.28 Million USD | 78.13% |
| 2009 Q1 | -98.76 Million USD | -8.25% |
| 2009 Q2 | -101.88 Million USD | -3.15% |
| 2009 Q4 | -53.55 Million USD | -140.33% |
| 2009 FY | -53.55 Million USD | 41.3% |
| 2008 FY | -91.23 Million USD | 37.45% |
| 2008 Q2 | -119.56 Million USD | 5.08% |
| 2008 Q3 | -118.07 Million USD | 1.25% |
| 2008 Q1 | -125.95 Million USD | 13.65% |
| 2008 Q4 | -91.23 Million USD | 22.73% |
| 2007 Q4 | -145.86 Million USD | -563.54% |
| 2007 FY | -145.86 Million USD | -723.98% |
| 2007 Q3 | 31.46 Million USD | -23.31% |
| 2007 Q2 | 41.03 Million USD | 64.66% |
| 2007 Q1 | 24.92 Million USD | 6.6% |
| 2006 Q3 | 77.59 Million USD | -12.64% |
| 2006 FY | 23.37 Million USD | 198.02% |
| 2006 Q1 | 68.4 Million USD | 772.0% |
| 2006 Q2 | 88.82 Million USD | 29.86% |
| 2006 Q4 | 23.37 Million USD | -69.87% |
| 2005 Q1 | -35.32 Million USD | 50.19% |
| 2005 Q4 | 7.84 Million USD | -88.34% |
| 2005 Q3 | 67.28 Million USD | 129.1% |
| 2005 Q2 | 29.37 Million USD | 183.15% |
| 2005 FY | 7.84 Million USD | 111.06% |
| 2004 Q4 | -70.91 Million USD | 19.29% |
| 2004 FY | -70.91 Million USD | 19.75% |
| 2004 Q1 | -93.17 Million USD | -5.44% |
| 2004 Q2 | -93.1 Million USD | 0.07% |
| 2004 Q3 | -87.86 Million USD | 5.63% |
| 2003 Q2 | -48.61 Million USD | -3.56% |
| 2003 Q4 | -88.36 Million USD | -917.19% |
| 2003 FY | -88.36 Million USD | -70.79% |
| 2003 Q1 | -46.93 Million USD | 9.27% |
| 2003 Q3 | 10.81 Million USD | 122.24% |
| 2002 FY | -51.73 Million USD | 1.81% |
| 2002 Q1 | -47.61 Million USD | 9.63% |
| 2002 Q2 | -46.7 Million USD | 1.91% |
| 2002 Q3 | -43.54 Million USD | 6.78% |
| 2002 Q4 | -51.73 Million USD | -18.83% |
| 2001 Q4 | -52.69 Million USD | -0.3% |
| 2001 Q3 | -52.53 Million USD | -152.0% |
| 2001 Q2 | 101.02 Million USD | -4.78% |
| 2001 Q1 | 106.09 Million USD | -1.74% |
| 2001 FY | -52.69 Million USD | -148.8% |
| 2000 FY | 107.98 Million USD | -3.76% |
| 2000 Q4 | 107.98 Million USD | -0.97% |
| 2000 Q1 | 109.78 Million USD | -2.15% |
| 2000 Q3 | 109.03 Million USD | -3.5% |
| 2000 Q2 | 112.98 Million USD | 2.92% |
| 1999 Q1 | 110.2 Million USD | -5.89% |
| 1999 Q3 | 104.7 Million USD | -2.6% |
| 1999 Q4 | 112.19 Million USD | 7.16% |
| 1999 FY | 112.19 Million USD | -4.19% |
| 1999 Q2 | 107.5 Million USD | -2.45% |
| 1998 FY | 117.1 Million USD | -0.51% |
| 1998 Q1 | 117.9 Million USD | 0.17% |
| 1998 Q2 | 112.1 Million USD | -4.92% |
| 1998 Q3 | 114.2 Million USD | 1.87% |
| 1998 Q4 | 117.1 Million USD | 2.54% |
| 1997 FY | 117.7 Million USD | 81.08% |
| 1997 Q4 | 117.7 Million USD | 4.34% |
| 1997 Q3 | 112.8 Million USD | 18.24% |
| 1997 Q2 | 95.4 Million USD | 26.53% |
| 1997 Q1 | 75.4 Million USD | 16.0% |
| 1996 Q1 | 67.8 Million USD | 74.29% |
| 1996 Q2 | 80.2 Million USD | 18.29% |
| 1996 Q3 | 71.5 Million USD | -10.85% |
| 1996 Q4 | 65 Million USD | -9.09% |
| 1996 FY | 65 Million USD | 67.1% |
| 1995 Q3 | 40.1 Million USD | 26.9% |
| 1995 Q4 | 38.9 Million USD | -2.99% |
| 1995 FY | 38.9 Million USD | 69.13% |
| 1995 Q1 | 23.9 Million USD | 3.91% |
| 1995 Q2 | 31.6 Million USD | 32.22% |
| 1994 Q4 | 23 Million USD | -19.58% |
| 1994 FY | 23 Million USD | 32.95% |
| 1994 Q1 | 26.7 Million USD | 54.34% |
| 1994 Q2 | 26.2 Million USD | -1.87% |
| 1994 Q3 | 28.6 Million USD | 9.16% |
| 1993 Q4 | 17.3 Million USD | -15.61% |
| 1993 Q1 | 18 Million USD | 1.69% |
| 1993 Q2 | 18.5 Million USD | 2.78% |
| 1993 FY | 17.3 Million USD | -2.26% |
| 1993 Q3 | 20.5 Million USD | 10.81% |
| 1992 Q1 | 15.2 Million USD | 137.5% |
| 1992 Q2 | 18.7 Million USD | 23.03% |
| 1992 Q3 | 19.8 Million USD | 5.88% |
| 1992 Q4 | 17.7 Million USD | -10.61% |
| 1992 FY | 17.7 Million USD | 176.56% |
| 1991 FY | 6.4 Million USD | -4.48% |
| 1991 Q2 | 5.2 Million USD | -11.86% |
| 1991 Q3 | 6.2 Million USD | 19.23% |
| 1991 Q4 | 6.4 Million USD | 3.23% |
| 1991 Q1 | 5.9 Million USD | -11.94% |
| 1990 Q3 | 6.4 Million USD | 12.28% |
| 1990 Q1 | 4.6 Million USD | -23.33% |
| 1990 Q2 | 5.7 Million USD | 23.91% |
| 1990 FY | 6.7 Million USD | 11.67% |
| 1990 Q4 | 6.7 Million USD | 4.69% |
| 1989 Q4 | 6 Million USD | -24.05% |
| 1989 Q3 | 7.9 Million USD | 6.76% |
| 1989 Q2 | 7.4 Million USD | 0.0% |
| 1989 FY | 6 Million USD | -24.05% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 85.268% |
| Alkermes plc | -166.73 Million USD | 95.058% |
| Agenus Inc. | 274.13 Million USD | 103.006% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.441% |
| Aptorum Group Limited | 1.35 Million USD | 707.275% |
| Ardelyx, Inc. | 34.51 Million USD | 123.879% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 292.547% |
| Bicycle Therapeutics plc | -481.46 Million USD | 98.288% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 122.788% |
| ChromaDex Corporation | -24.04 Million USD | 65.731% |
| Chimerix, Inc. | -25.51 Million USD | 67.704% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 218.268% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 65.194% |
| CRISPR Therapeutics AG | -150.84 Million USD | 94.537% |
| Precision BioSciences, Inc. | -85.41 Million USD | 90.351% |
| Dyadic International, Inc. | -6.37 Million USD | -29.208% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 48.277% |
| Fortress Biotech, Inc. | 7.66 Million USD | 207.515% |
| Lantern Pharma Inc. | -21.7 Million USD | 62.029% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 92.545% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 3.537% |
| Incyte Corporation | -3.17 Billion USD | 99.74% |
| IO Biotech, Inc. | -140.69 Million USD | 94.143% |
| Jaguar Health, Inc. | 29.39 Million USD | 128.039% |
| Novavax, Inc. | -298.29 Million USD | 97.237% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 254.413% |
| Opthea Limited | 28.15 Million USD | 129.268% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 50.914% |
| ContextLogic Inc. | -232 Million USD | 96.448% |
| MiMedx Group, Inc. | -33.9 Million USD | 75.691% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 180.834% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -255.671% |
| NextCure, Inc. | -6.47 Million USD | -27.235% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 83.682% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -29.19% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 167.753% |
| Vaxcyte, Inc. | -368.22 Million USD | 97.762% |
| PDS Biotechnology Corporation | -32.7 Million USD | 74.805% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 147.696% |
| Pharming Group N.V. | 109.8 Million USD | 107.505% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 52.627% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 95.297% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 55.502% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 55.502% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -16.07% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -40.631% |
| Acelyrin, Inc. | -216.9 Million USD | 96.201% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -46.891% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -378.016% |
| Summit Therapeutics Inc. | 34.67 Million USD | 123.767% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -21.138% |
| Senti Biosciences, Inc. | 1.74 Million USD | 573.621% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 95.536% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 89.36% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -35.945% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 8360.081% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 1412.261% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 92.959% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 95.101% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 107.433% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -8.491% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 93.617% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 219.528% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 96.6% |
| Immix Biopharma, Inc. | -17.5 Million USD | 52.935% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 97.398% |
| MEI Pharma, Inc. | -3.7 Million USD | -122.429% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 165.87% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 105.095% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 129.651% |
| Fortress Biotech, Inc. | 7.66 Million USD | 207.515% |
| Precigen, Inc. | -481 Thousand USD | -1613.306% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 158.526% |
| AlloVir, Inc. | -62.69 Million USD | 86.855% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 85.182% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 113.364% |
| ImmuCell Corporation | 10.99 Million USD | 174.983% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 94.654% |
| Onconetix, Inc. | 5.33 Million USD | 254.574% |
| PureTech Health plc | -167.19 Million USD | 95.071% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 72.945% |
| Elevation Oncology, Inc. | -19.11 Million USD | 56.894% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -67.875% |
| Seer, Inc. | -4.24 Million USD | -94.363% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 65.715% |
| Innoviva, Inc. | 255.56 Million USD | 103.225% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 85.248% |
| ESSA Pharma Inc. | -33.62 Million USD | 75.489% |
| GlycoMimetics, Inc. | -40.98 Million USD | 79.892% |
| GT Biopharma, Inc. | -1.02 Million USD | -707.15% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 87.842% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 113.453% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 93.854% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 40.524% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 71.457% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -10839.284% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 73.297% |
| Aptose Biosciences Inc. | -8.19 Million USD | -0.563% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -163.373% |
| Soligenix, Inc. | -4.95 Million USD | -66.431% |
| Century Therapeutics, Inc. | 847 Thousand USD | 1072.963% |
| Kura Oncology, Inc. | -20.11 Million USD | 59.037% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 79.864% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 1.869% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 552.381% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -157.773% |
| Autolus Therapeutics plc | -186.59 Million USD | 95.584% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 83.285% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 97.012% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 124.049% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 105.014% |
| GRI Bio, Inc. | -1.79 Million USD | -359.365% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 8.261% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 75.22% |
| IGM Biosciences, Inc. | -72.6 Million USD | 88.65% |
| INmune Bio, Inc. | -25.41 Million USD | 67.569% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 105.459% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 83.732% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 49.284% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -185.657% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 121.678% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 79.99% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 125.846% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 102.18% |
| Verastem, Inc. | -37.27 Million USD | 77.893% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 9.17% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 84.11% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 45.55% |
| Histogen Inc. | -7.48 Million USD | -10.071% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 61.859% |
| Surrozen, Inc. | -32.66 Million USD | 74.77% |
| Organovo Holdings, Inc. | -1.5 Million USD | -446.848% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -96.051% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 143.465% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 415.023% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 298.292% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 1.672% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 81.03% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 43.465% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 97.399% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -1041.318% |
| Apollomics, Inc. | -27.39 Million USD | 69.918% |
| Amarin Corporation plc | -191.04 Million USD | 95.686% |
| Mesoblast Limited | 55.96 Million USD | 114.726% |
| Turnstone Biologics Corp. | -14.58 Million USD | 43.493% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 67.417% |
| Synaptogenix, Inc. | -28.66 Million USD | 71.247% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -780.449% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 116.911% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -855.934% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -13.417% |
| Exelixis, Inc. | -73.05 Million USD | 88.719% |
| Better Therapeutics, Inc. | -860 Thousand USD | -858.256% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 65.681% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 96.586% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 1219.601% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -10.794% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 757.177% |
| Gritstone bio, Inc. | 39.49 Million USD | 120.869% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 90.201% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -213.091% |
| Avid Bioservices, Inc. | 169.72 Million USD | 104.855% |
| Insmed Incorporated | 721.62 Million USD | 101.142% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 9.851% |
| MediWound Ltd. | -5.32 Million USD | -54.848% |
| OmniAb, Inc. | 9.2 Million USD | 189.547% |
| Alector, Inc. | -35.63 Million USD | 76.875% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 109.586% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -67.228% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 162.248% |
| Zai Lab Limited | -775 Million USD | 98.937% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 102.42% |
| Aura Biosciences, Inc. | -21.52 Million USD | 61.714% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 90.008% |
| Immunic, Inc. | -45.34 Million USD | 81.824% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 95.735% |
| Veracyte, Inc. | -203.82 Million USD | 95.957% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 101.291% |
| FibroGen, Inc. | 56.76 Million USD | 114.517% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 192.544% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -191.502% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -298.049% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.18% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -146.663% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 95.034% |
| TG Therapeutics, Inc. | 17.86 Million USD | 146.137% |
| Galecto, Inc. | -21.21 Million USD | 61.157% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 65.352% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 100.525% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 66.325% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 28.383% |
| XBiotech Inc. | -200.02 Million USD | 95.88% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 90.201% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 282.001% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 76.63% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 89.328% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 244.808% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 95.164% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 91.079% |
| Vaxxinity, Inc. | 10.13 Million USD | 181.336% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 101.119% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 23.464% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 87.505% |
| NexImmune, Inc. | -3.13 Million USD | -162.985% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -138.685% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 45.465% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 69.59% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 8.189% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -6515.292% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 79.688% |
| Ainos, Inc. | 4.07 Million USD | 302.088% |
| Pluri Inc. | 22.82 Million USD | 136.099% |
| Prothena Corporation plc | -608.34 Million USD | 98.645% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 93.061% |
| Celularity Inc. | 65.19 Million USD | 112.642% |
| Rallybio Corporation | -24.1 Million USD | 65.808% |
| Cue Biopharma, Inc. | -33.81 Million USD | 75.632% |
| MeiraGTx Holdings plc | -40.3 Million USD | 79.552% |
| Omeros Corporation | 331.17 Million USD | 102.488% |
| Humacyte, Inc. | -22.48 Million USD | 63.351% |
| Immunocore Holdings plc | -358.59 Million USD | 97.702% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 66.466% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 73.331% |
| Blueprint Medicines Corporation | 702.83 Million USD | 101.173% |
| CalciMedica, Inc. | -5.53 Million USD | -49.024% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 95.622% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 19.317% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 79.417% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 75.217% |
| Pulmatrix, Inc. | -10.41 Million USD | 20.889% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -37.879% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 78.394% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 92.602% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 86.252% |
| Cytokinetics, Incorporated | 642.37 Million USD | 101.283% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -41.525% |
| Nutriband Inc. | -251.65 Thousand USD | -3174.695% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 75.846% |
| Vor Biopharma Inc. | 4.3 Million USD | 291.651% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.863% |
| Evogene Ltd. | -19.63 Million USD | 58.027% |
| ProKidney Corp. | -56.23 Million USD | 85.346% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 83.068% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 10.785% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 100.604% |
| CorMedix Inc. | -43.05 Million USD | 80.858% |
| BioLineRx Ltd. | 7.33 Million USD | 212.336% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 69.995% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 117.858% |
| Atai Life Sciences N.V. | -28.55 Million USD | 71.143% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 469.464% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 63.881% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 146.467% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 89.023% |
| MediciNova, Inc. | -50.78 Million USD | 83.772% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 89.543% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -36534.808% |
| GeoVax Labs, Inc. | -6.45 Million USD | -27.716% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 95.876% |
| Biomea Fusion, Inc. | -166.57 Million USD | 95.053% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 95.395% |
| Mereo BioPharma Group plc | -51.46 Million USD | 83.988% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 91.311% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 97.195% |
| Absci Corporation | -72.59 Million USD | 88.648% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 280.486% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 96.485% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 91.253% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 91.388% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 78.909% |
| Allakos Inc. | -24.97 Million USD | 67.003% |
| Imunon, Inc. | -4.21 Million USD | -95.569% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 44.098% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 93.914% |
| BioAtla, Inc. | -109.01 Million USD | 92.44% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 1219.601% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -777.636% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 168.87% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 61.133% |
| XOMA Corporation | -29 Million USD | 71.583% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 50.236% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 8.596% |
| aTyr Pharma, Inc. | -7.44 Million USD | -10.632% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 93.388% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 96.041% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 89.923% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 91.116% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -859.166% |
| Akari Therapeutics, Plc | -3.84 Million USD | -114.33% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 607.798% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.597% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -593.608% |
| UroGen Pharma Ltd. | 4.39 Million USD | 287.679% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 107.262% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 11551.877% |
| Orgenesis Inc. | 21.78 Million USD | 137.831% |
| Entera Bio Ltd. | -10.62 Million USD | 22.467% |
| GH Research PLC | -78.07 Million USD | 89.445% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 63.025% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 69.087% |
| Xencor, Inc. | 29.64 Million USD | 127.8% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -318.365% |
| Replimune Group, Inc. | 1.41 Million USD | 683.64% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -3264.937% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 93.481% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -593.608% |
| Portage Biotech Inc. | -4.98 Million USD | -65.449% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -36534.808% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 87.537% |
| OncoCyte Corporation | -6.56 Million USD | -25.568% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 1018.306% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -80.897% |
| Purple Biotech Ltd. | -14.13 Million USD | 41.71% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 65.31% |
| scPharmaceuticals Inc. | -6.54 Million USD | -25.913% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 50.63% |
| HilleVax, Inc. | -165.48 Million USD | 95.02% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -224.704% |
| Tharimmune, Inc. | -10.93 Million USD | 24.639% |
| Genprex, Inc. | -6.73 Million USD | -22.313% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 97.765% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 90.684% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -488.223% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -148.451% |
| OKYO Pharma Limited | -826.84 Thousand USD | -896.677% |
| Savara Inc. | 153 Thousand USD | 5486.275% |
| Curis, Inc. | -23.88 Million USD | 65.5% |
| Daré Bioscience, Inc. | -5.15 Million USD | -59.774% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -961.968% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -32.748% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 795.443% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.634% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 166.791% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 98.645% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 95.559% |
| Erasca, Inc. | -37.21 Million USD | 77.856% |
| bluebird bio, Inc. | 108.57 Million USD | 107.59% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -539.882% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 102.176% |
| DBV Technologies S.A. | -126.98 Million USD | 93.51% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -539.882% |
| Moderna, Inc. | -2.9 Billion USD | 99.717% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 20.392% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 24.172% |
| Molecular Templates, Inc. | 707 Thousand USD | 1265.629% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 73.731% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 102.378% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 89.958% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 91.016% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 74.464% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 76.027% |
| MacroGenics, Inc. | -66.98 Million USD | 87.697% |
| RenovoRx, Inc. | -1.17 Million USD | -602.558% |
| Adicet Bio, Inc. | -138.78 Million USD | 94.062% |
| Prime Medicine, Inc. | -27.94 Million USD | 70.506% |
| Aditxt, Inc. | 18.12 Million USD | 145.478% |
| Adagene Inc. | -87.62 Million USD | 90.595% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -97.843% |
| Quantum-Si incorporated | -118.55 Million USD | 93.049% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 122.888% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -10.259% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 83.011% |
| SciSparc Ltd. | -2.06 Million USD | -299.08% |
| Vericel Corporation | 1.27 Million USD | 745.341% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 31.277% |
| Minerva Neurosciences, Inc. | 41 Million USD | 120.098% |
| Generation Bio Co. | 31.44 Million USD | 126.205% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 95.301% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 73.35% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 107.068% |
| Invivyd, Inc. | -198.47 Million USD | 95.848% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 90.871% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -243.706% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 88.359% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -20.747% |
| 2seventy bio, Inc. | 181.71 Million USD | 104.535% |
| ADMA Biologics, Inc. | 90.06 Million USD | 109.15% |
| Clene Inc. | 3.34 Million USD | 346.737% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 9.267% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 61.689% |
| GeoVax Labs, Inc. | -6.45 Million USD | -27.716% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 97.605% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 68.303% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 104.638% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -101.414% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 264.754% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -58.207% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 93.676% |
| Evaxion Biotech A/S | 5.28 Million USD | 255.877% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 92.679% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 93.722% |
| Trevena, Inc. | 2.25 Million USD | 464.969% |
| Surrozen, Inc. | -32.66 Million USD | 74.77% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 84.001% |
| Cingulate Inc. | 3.08 Million USD | 367.332% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -180.592% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 214.665% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 11.303% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 89.611% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 93.731% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 92.192% |
| Clearmind Medicine Inc. | -3.94 Million USD | -109.023% |
| Kronos Bio, Inc. | -36.05 Million USD | 77.143% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 187.586% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 665.177% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 84.811% |
| Statera Biopharma, Inc. | 14.41 Million USD | 157.164% |
| ImmunityBio, Inc. | 618.22 Million USD | 101.333% |
| Korro Bio, Inc. | -132.94 Million USD | 93.801% |
| Kineta, Inc. | -4.54 Million USD | -81.48% |
| BioVie Inc. | -17.73 Million USD | 53.526% |
| Codexis, Inc. | -43.27 Million USD | 80.955% |
| Celularity Inc. | 65.19 Million USD | 112.642% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -160.05% |
| Celcuity Inc. | 6.78 Million USD | 221.486% |
| Virax Biolabs Group Limited | -3.36 Million USD | -144.907% |
| Cibus, Inc. | -8.07 Million USD | -2.018% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -94.869% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 280.328% |
| IN8bio, Inc. | -16.38 Million USD | 49.716% |
| Kodiak Sciences Inc. | -103.87 Million USD | 92.066% |
| Annexon, Inc. | -193.75 Million USD | 95.747% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 22991.667% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 52.906% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -134.586% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.782% |
| Eyenovia, Inc. | 1.25 Million USD | 754.722% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 130.63% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -154.117% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 75.213% |
| Arcellx, Inc. | -296.95 Million USD | 97.225% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 57.751% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 86.003% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 60.24% |
| Moolec Science SA | 117.61 Thousand USD | 7106.7% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 78.539% |
| Geron Corporation | 14.76 Million USD | 155.83% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 78.266% |
| Royalty Pharma plc | 5.65 Billion USD | 100.146% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 94.173% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -17.907% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -53.668% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 94.144% |
| Humacyte, Inc. | -22.48 Million USD | 63.351% |
| Structure Therapeutics Inc. | -124.33 Million USD | 93.372% |
| 89bio, Inc. | -289.05 Million USD | 97.149% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 67.352% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -362.199% |
| Genelux Corporation | -6.89 Million USD | -19.452% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 73.467% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 109.858% |
| Notable Labs, Ltd. | -9.77 Million USD | 15.702% |
| Liquidia Corporation | -80.17 Million USD | 89.721% |
| Mustang Bio, Inc. | -3.73 Million USD | -120.584% |
| Immunovant, Inc. | -635.22 Million USD | 98.703% |
| Quantum-Si incorporated | -118.55 Million USD | 93.049% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 53.08% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -98.914% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 202.666% |
| Acasti Pharma Inc. | -23 Million USD | 64.177% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -144.741% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 49.284% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 94.017% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -164.443% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 62.932% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 55.62% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 95.132% |
| PepGen Inc. | -60.67 Million USD | 86.417% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 64.132% |
| United Therapeutics Corporation | -507.7 Million USD | 98.377% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 56.912% |
| Solid Biosciences Inc. | -47.75 Million USD | 82.741% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -855.934% |
| Immuneering Corporation | -54.94 Million USD | 85.001% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -96.051% |
| Silo Pharma, Inc. | -3.52 Million USD | -133.833% |
| Belite Bio, Inc | -87.27 Million USD | 90.557% |
| XOMA Corporation | -29 Million USD | 71.583% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 88.343% |
| Bionomics Limited | 227 Million USD | 103.63% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 92.913% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -225.345% |
| uniQure N.V. | -102.95 Million USD | 91.995% |
| Cassava Sciences, Inc. | -121.13 Million USD | 93.197% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -97.843% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 120.124% |
| Forte Biosciences, Inc. | -11.96 Million USD | 31.101% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -166.337% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 7874.528% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -154.117% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 192.544% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -11.125% |
| Altimmune, Inc. | -134.48 Million USD | 93.872% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 104.161% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -225.345% |
| Compugen Ltd. | -12.9 Million USD | 36.136% |
| Peak Bio, Inc. | 10.34 Million USD | 179.699% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -2812.014% |
| Benitec Biopharma Inc. | -50.58 Million USD | 83.708% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 92.102% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 141.95% |
| Zura Bio Limited | -99.8 Million USD | 91.743% |
| PolyPid Ltd. | 6.17 Million USD | 233.566% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 111.118% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 141.95% |
| Instil Bio, Inc. | 75.35 Million USD | 110.936% |
| argenx SE | -2.02 Billion USD | 99.594% |
| Immunome, Inc. | -97.02 Million USD | 91.507% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 63.365% |
| Verona Pharma plc | -220.44 Million USD | 96.262% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 88.513% |
| Shattuck Labs, Inc. | -121.42 Million USD | 93.213% |
| CervoMed Inc. | -7.79 Million USD | -5.751% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 95.557% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -88.452% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 93.744% |
| Moolec Science SA | 117.61 Thousand USD | 7106.7% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -260.187% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 151.835% |
| AnaptysBio, Inc. | -18.15 Million USD | 54.598% |
| Design Therapeutics, Inc. | -18.15 Million USD | 54.595% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 88.291% |
| NeurAxis, Inc. | 145.7 Thousand USD | 5756.143% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 173.371% |
| Lumos Pharma, Inc. | -28.49 Million USD | 71.077% |
| Achilles Therapeutics plc | -126.92 Million USD | 93.507% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 88.513% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -1156.767% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 60.33% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 665.177% |
| Nutriband Inc. | -251.65 Thousand USD | -3174.695% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 37.431% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -10.766% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 102.422% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 134.721% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 98.158% |
| Palisade Bio, Inc. | -12.06 Million USD | 31.684% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 94.127% |
| Beam Therapeutics Inc. | -262.72 Million USD | 96.863% |
| Neurogene Inc. | -131.95 Million USD | 93.755% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 137.775% |
| AEON Biopharma, Inc. | -4.88 Million USD | -68.873% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 97.815% |
| Sesen Bio, Inc. | -112.55 Million USD | 92.678% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 91.747% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -251.011% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 78.883% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 90.105% |
| Athira Pharma, Inc. | -88.99 Million USD | 90.74% |
| Vaccinex, Inc. | -1.28 Million USD | -539.829% |
| HCW Biologics Inc. | 2.85 Million USD | 388.482% |
| XOMA Corporation | -29 Million USD | 71.583% |
| Nektar Therapeutics | 210.24 Million USD | 103.92% |
| Arvinas, Inc. | -313.8 Million USD | 97.374% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 607.798% |
| Merus N.V. | -192.88 Million USD | 95.727% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 113.738% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -18.781% |
| Rezolute, Inc. | -68.16 Million USD | 87.911% |
| Clene Inc. | 3.34 Million USD | 346.737% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 37.507% |
| BeyondSpring Inc. | -13.75 Million USD | 40.087% |
| Synlogic, Inc. | -6.68 Million USD | -23.276% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 826.72% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 2.531% |
| Peak Bio, Inc. | 10.34 Million USD | 179.699% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 90.001% |
| Krystal Biotech, Inc. | -350.23 Million USD | 97.647% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 106.639% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 95.124% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -161.027% |
| MannKind Corporation | 143.89 Million USD | 105.727% |
| Ikena Oncology, Inc. | -109.15 Million USD | 92.45% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -8.85% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 75.103% |
| Gossamer Bio, Inc. | 180.35 Million USD | 104.569% |
| CohBar, Inc. | -5.93 Million USD | -38.954% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 72.297% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 280.486% |
| Legend Biotech Corporation | -949.39 Million USD | 99.132% |
| Mural Oncology plc | -255.84 Million USD | 96.779% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 125.581% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -74.944% |
| Disc Medicine, Inc. | -358.28 Million USD | 97.7% |
| Champions Oncology, Inc. | 4.81 Million USD | 271.259% |
| REGENXBIO Inc. | 54.76 Million USD | 115.047% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -2964.628% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 94.543% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 8.555% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 89.786% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 83.577% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 93.519% |
| Cellectis S.A. | -43.85 Million USD | 81.209% |
| Longeveron Inc. | -2.9 Million USD | -183.391% |
| Repare Therapeutics Inc. | -107.85 Million USD | 92.359% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 100.851% |
| Inozyme Pharma, Inc. | 12 Million USD | 168.652% |
| Revolution Medicines, Inc. | -608.2 Million USD | 98.645% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -570.0% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 96.892% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 94.509% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 47.332% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -1013.649% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.914% |
| Denali Therapeutics Inc. | -74.86 Million USD | 88.992% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 31.277% |
| Veru Inc. | 4.77 Million USD | 272.407% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 26.721% |
| Cingulate Inc. | 3.08 Million USD | 367.332% |
| Passage Bio, Inc. | 4.58 Million USD | 279.738% |
| Context Therapeutics Inc. | -14.44 Million USD | 42.968% |
| Exicure, Inc. | 5.84 Million USD | 240.896% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 96.423% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 79.174% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 152.521% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 85.99% |
| Nuvalent, Inc. | -335.38 Million USD | 97.543% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 575.166% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 88.936% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 7.3% |
| OmniAb, Inc. | 9.2 Million USD | 189.547% |
| Anew Medical, Inc. | 1.43 Million USD | 675.302% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 150.306% |
| Lipocine Inc. | -4.75 Million USD | -73.327% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 92.496% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 154.107% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 83.732% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 133.107% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -22.616% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 87.481% |
| Ocugen, Inc. | -32.52 Million USD | 74.659% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 90.37% |
| Q32 Bio Inc. | -37.94 Million USD | 78.283% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -1212.261% |
| Alumis Inc. Common Stock | -13.52 Million USD | 39.086% |
| Equillium, Inc. | -22.39 Million USD | 63.197% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 67.768% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 74.742% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -3224.123% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 106.148% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 357.692% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 2609.126% |
| Dominari Holdings Inc. | 195 Thousand USD | 4326.154% |
| Edesa Biotech, Inc. | -5.26 Million USD | -56.467% |
| vTv Therapeutics Inc. | -8.91 Million USD | 7.581% |
| Bio-Techne Corporation | 267.74 Million USD | 103.078% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 49.158% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 93.022% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 1.928% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 34.859% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 96.638% |
| Nkarta, Inc. | 57.29 Million USD | 114.382% |
| BioCardia, Inc. | 212 Thousand USD | 3987.264% |
| Iterum Therapeutics plc | 13.43 Million USD | 161.326% |